Literature DB >> 10502520

Evaluation of antibody parameters as potential correlates of protection or enhancement by experimental vaccines to equine infectious anemia virus.

S A Hammond1, M L Raabe, C J Issel, R C Montelaro.   

Abstract

We previously demonstrated in trials of a variety of experimental vaccines to equine infectious anemia virus (EIAV) a remarkable spectrum of efficacy ranging from sterilizing protection to severe enhancement of virus replication and disease, depending on the immunization strategy used. This range of vaccine efficacy observed in vivo offers a unique opportunity for evaluating potential in vitro immune correlates of protection and enhancement. We describe here a comprehensive analysis and comparison of EIAV envelope-specific antibody responses elicited by attenuated, inactivated whole virus and envelope subunit vaccines to EIAV, and we evaluate the potential of in vitro antibody assays as correlates of protection or enhancement. Thus vaccine-induced serum antibody responses in experimentally immunized ponies at the day of challenge were assayed using a panel of quantitative, qualitative, and functional in vitro assays, including end-point titer of total and isotypic IgG, serum antibody avidity, conformational dependence, and serum neutralization. The results of these studies revealed substantial differences in the EIAV envelope-specific antibody responses elicited by the different vaccines, indicating the importance of envelope glycoprotein antigen presentation in determining the specificity of vaccine immunity. Although no single in vitro parameter provided a statistically significant correlate of protection or enhancement, the use of multiple parameters (titer, avidity index, and conformation ratio) could be used as a reliable correlate of vaccine protection and that the level of vaccine protection was closely associated with the development of mature antibody responses. These studies demonstrate the importance of using multiple antibody assays to evaluate lentiviral vaccine responses and emphasize the need for the development of new in vitro antibody assays that may provide more insight into vaccine protection and enhancement. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10502520     DOI: 10.1006/viro.1999.9939

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  18 in total

1.  Immune responses and viral replication in long-term inapparent carrier ponies inoculated with equine infectious anemia virus.

Authors:  S A Hammond; F Li; B M McKeon; S J Cook; C J Issel; R C Montelaro
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

2.  Immune suppression of challenged vaccinates as a rigorous assessment of sterile protection by lentiviral vaccines.

Authors:  Jodi K Craigo; Shannon Durkin; Timothy J Sturgeon; Tara Tagmyer; Sheila J Cook; Charles J Issel; Ronald C Montelaro
Journal:  Vaccine       Date:  2006-09-22       Impact factor: 3.641

3.  Development of a high throughput, semi-automated, infectious center cell-based ELISA for equine infectious anemia virus.

Authors:  Jodi K Craigo; Corin Ezzelarab; Ronald C Montelaro
Journal:  J Virol Methods       Date:  2012-07-20       Impact factor: 2.014

4.  Discerning an effective balance between equine infectious anemia virus attenuation and vaccine efficacy.

Authors:  Jodi K Craigo; Feng Li; Jonathan D Steckbeck; Shannon Durkin; Laryssa Howe; Sheila J Cook; Charles Issel; Ronald C Montelaro
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

5.  Divergence, not diversity of an attenuated equine lentivirus vaccine strain correlates with protection from disease.

Authors:  Jodi K Craigo; Shannon Barnes; Sheila J Cook; Charles J Issel; Ronald C Montelaro
Journal:  Vaccine       Date:  2010-10-16       Impact factor: 3.641

6.  Fc receptor-mediated immune responses: new tools but increased complexity in HIV prevention.

Authors:  Diego A Vargas-Inchaustegui; Marjorie Robert-Guroff
Journal:  Curr HIV Res       Date:  2013-07       Impact factor: 1.581

7.  Epitope shifting of gp90-specific cellular immune responses in EIAV-infected ponies.

Authors:  Chong Liu; Sheila J Cook; Jodi K Craigo; Frank R Cook; Charles J Issel; Ronald C Montelaro; David W Horohov
Journal:  Vet Immunol Immunopathol       Date:  2014-08-10       Impact factor: 2.046

8.  Envelope determinants of equine infectious anemia virus vaccine protection and the effects of sequence variation on immune recognition.

Authors:  Tara L Tagmyer; Jodi K Craigo; Sheila J Cook; Deborah L Even; Charles J Issel; Ronald C Montelaro
Journal:  J Virol       Date:  2008-01-30       Impact factor: 5.103

9.  Viral load and clinical disease enhancement associated with a lentivirus cytotoxic T lymphocyte vaccine regimen.

Authors:  Robert H Mealey; Steven R Leib; Matt H Littke; Bettina Wagner; David W Horohov; Travis C McGuire
Journal:  Vaccine       Date:  2009-02-24       Impact factor: 3.641

10.  An EIAV field isolate reveals much higher levels of subtype variability than currently reported for the equine lentivirus family.

Authors:  Jodi K Craigo; Shannon Barnes; Baoshan Zhang; Sheila J Cook; Laryssa Howe; Charles J Issel; Ronald C Montelaro
Journal:  Retrovirology       Date:  2009-10-20       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.